Literature DB >> 16624293

Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome.

Sarah Clark1, Jennifer Schwalbe, Melissa R Stasko, Paul J Yarowsky, Alberto C S Costa.   

Abstract

The Ts65Dn mouse, an adult model of Down syndrome displays behavioral deficits consistent with a dysfunctional hippocampus, similar to that seen with DS. In looking for mechanisms underlying these performance deficits, we have assessed adult neurogenesis in the dentate gyrus of Ts65Dn. Under untreated conditions, Ts65Dn mice (2-5 months old) showed markedly fewer BrdU-labeled cells than euploid animals. Chronic antidepressant treatment for over 3 weeks with the serotonin selective reuptake inhibitor, fluoxetine, increased neurogenesis in the Ts65Dn to comparable levels seen in the euploid by augmenting both proliferation and survival of BrdU-labeled cells in the subgranular layer and granule cell layer of the hippocampus, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624293     DOI: 10.1016/j.expneurol.2006.02.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  54 in total

1.  Altered distribution of hippocampal interneurons in the murine Down Syndrome model Ts65Dn.

Authors:  Samuel Hernández-González; Raúl Ballestín; Rosa López-Hidalgo; Javier Gilabert-Juan; José Miguel Blasco-Ibáñez; Carlos Crespo; Juan Nácher; Emilio Varea
Journal:  Neurochem Res       Date:  2014-11-16       Impact factor: 3.996

2.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

Review 3.  The cognitive phenotype of Down syndrome: insights from intracellular network analysis.

Authors:  Avi Ma'ayan; Katheleen Gardiner; Ravi Iyengar
Journal:  NeuroRx       Date:  2006-07

4.  The proteins of human chromosome 21.

Authors:  Katheleen Gardiner; Alberto C S Costa
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-08-15       Impact factor: 3.908

Review 5.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 6.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

Review 7.  Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior.

Authors:  Syed Mohammed Qasim Hussaini; Chan-Il Choi; Chang Hoon Cho; Hyo Jin Kim; Heechul Jun; Mi-Hyeon Jang
Journal:  Neurosci Biobehav Rev       Date:  2014-09-28       Impact factor: 8.989

8.  Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.

Authors:  Sina Shadfar; Yu-Gyeong Kim; Nikita Katila; Sabita Neupane; Uttam Ojha; Sunil Bhurtel; Sunil Srivastav; Gil-Saeng Jeong; Pil-Hoon Park; Jin Tae Hong; Dong-Young Choi
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

Review 9.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

10.  Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome.

Authors:  Chelsee A Hewitt; King-Hwa Ling; Tobias D Merson; Ken M Simpson; Matthew E Ritchie; Sarah L King; Melanie A Pritchard; Gordon K Smyth; Tim Thomas; Hamish S Scott; Anne K Voss
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.